CLYYF OTC
Celyad Oncology S.A.
1W: +0.0%
1M: +0.0%
3M: +12.0%
YTD: +86.7%
1Y: -31.7%
3Y: -99.4%
$0.28
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$186K
+82.4% ▲
5Y CAGR: +98.7%
Gross Profit
$919K
+2684.8% ▲
5Y CAGR: +173.5%
Operating Income
-$6M
+40.9% ▲
Net Income
-$6M
+31.1% ▲
EPS (Diluted)
$-0.14
+57.6% ▲
EBITDA
-$5M
+30.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $5K | $0 | $0 | $102K | $186K |
| YoY Growth | -16.7% | -100.0% | +0.0% | +0.0% | +82.4% |
| Cost of Revenue | $0 | $2M | $1M | $69K | -$733K |
| Gross Profit | $5K | -$2M | -$1M | $33K | $919K |
| Gross Margin | 100.0% | — | — | 32.4% | 494.1% |
| R&D Expenses | $22M | $19M | $18M | $5M | $3M |
| SG&A Expenses | $9M | $10M | $10M | $6M | $4M |
| Operating Expenses | $17M | $29M | $28M | $8M | $7M |
| Operating Income | -$17M | -$26M | -$29M | -$11M | -$6M |
| Operating Margin | -339740.0% | — | — | -10389.2% | -3365.1% |
| Interest Expense | $297K | $255K | $197K | $84K | $119K |
| Income Before Tax | -$17M | -$27M | -$41M | -$9M | -$6M |
| Tax Expense | $0 | $10K | $65K | -$191K | -$136K |
| Net Income | -$17M | -$27M | -$41M | -$8M | -$6M |
| Net Margin | -344080.0% | — | — | -8282.4% | -3131.2% |
| EPS (Diluted) | $-1.23 | $-1.70 | $-1.81 | $-0.33 | $-0.14 |
| EBITDA | -$16M | -$25M | -$40M | -$8M | -$5M |
| Shares Outstanding | 14M | 16M | 23M | 26M | 41M |